Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is thyroid hormone suppression therapy prothrombotic?

McDonald K Horne1, Kulvinder K Singh, Kathryn G Rosenfeld

  • 1Department of Laboratory Medicine, National Institutes of Health, Building 10, Room 2C-306, Bethesda, Maryland 20892, USA. MHorne@mail.cc.nih.gov

The Journal of Clinical Endocrinology and Metabolism
|September 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First serological evidence of circulation of equine rhinitis A virus and molecular detection of equine rhinitis B virus in horses in North Africa.

Veterinary research communications·2026
Same author

Pathways to Facilitate Early Recognition and Diagnosis of Hypochondroplasia.

Advances in therapy·2026
Same author

A Systematic Review of New, Enhanced Surveillance Systems and Methodologies for Zoonotic Influenza Viruses in Animals and Human-Animal Interface.

Influenza and other respiratory viruses·2025
Same author

Navigating the Future: Considerations for use of Continuous Glucose Monitoring in Diabetes Trials.

Therapeutic innovation & regulatory science·2025
Same author

Reducing Effects of Hospital-Associated Deconditioning in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Clinical journal of oncology nursing·2025
Same author

Role and Contribution of Serological Surveillance in Animals and Exposed Humans to the Study of Zoonotic Influenza Disease Epidemiology: A Scoping Review.

Pathogens (Basel, Switzerland)·2025

Chronic thyroid hormone suppression therapy (THST) may increase thrombosis risk. Patients on THST showed a prothrombotic profile, with higher levels of clotting factors and lower levels of anticoagulants compared to controls.

Area of Science:

  • Endocrinology
  • Hematology
  • Oncology

Background:

  • Thyroid hormone suppression therapy (THST) is a common treatment for thyroid cancer.
  • The potential prothrombotic effects of THST are not fully understood.
  • Assessing thrombotic risk in patients undergoing THST is crucial for patient management.

Purpose of the Study:

  • To investigate whether chronic THST is associated with a prothrombotic state.
  • To compare hemostatic markers in thyroid cancer patients during hyperthyroid (on THST) and hypothyroid states.
  • To evaluate differences in these markers between patients and healthy controls.

Main Methods:

  • Blood samples were collected from 14 thyroid cancer patients during THST and after withdrawal for radioiodine therapy.
  • Measurements included prothrombin fragment 1 + 2, fibrinogen, factor VIII, antithrombin, tissue plasminogen activator antigen (tPA), plasminogen activator inhibitor 1 (PAI-1), protein C, protein S, and plasmin-antiplasmin complexes.

Related Experiment Videos

  • Levels were compared between hyperthyroid and hypothyroid states and with healthy female controls.

    • Main Results:

    • Hyperthyroid state (on THST) showed significantly higher levels of prothrombin fragment 1 + 2, fibrinogen, factor VIII, antithrombin, tPA, PAI-1, and C-reactive protein compared to the hypothyroid state.
    • Protein C and plasmin-antiplasmin complexes were significantly lower during the hyperthyroid period.
    • Female patients on THST had higher levels of prothrombin fragment 1 + 2, fibrinogen, protein S, antithrombin, tPA, PAI-1, and PAI-1/tPA compared to healthy controls.

    Conclusions:

    • Evidence suggests that THST is associated with a prothrombotic profile in the majority of treated patients.
    • Thyroid hormone status significantly impacts various hemostatic markers.
    • Further research is warranted to elucidate the clinical implications of these findings for thrombotic risk.